Prevalence of DNA Mismatch Repair Deficiencies in Multiple Solid Tumor Types in China

Abstract

Aim: Microsatellite instability (MSI) as a result of deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) is a key contributor to the development of tumors with a high mutation rate and cancer-specific neoantigens. dMMR identification can be beneficial for selection of immune checkpoint inhibitor (ICI) therapy-eligible patients. While multiple studies have focused on dMMR prevalence in colorectal cancer (CRC), fewer investigate the prevalence of dMMR in tumor types besides CRC, especially in Chinese patients. In this study, we aimed to determine the prevalence of dMMR in China across five gastrointestinal and gynecological tumor types.

Methods: Tissue samples from Chinese patients with advanced endometrial, ovarian, cervical, biliary tract, or gastric metastatic or unresectable solid tumors were tested for dMMR status using immunohistochemistry with the Ventana MMR RxDx panel. Data were analyzed to determine the prevalence of dMMR for each tumor type.

Results: A total of 748 patients were included in the study, representing five tumor types. Prevalence of dMMR varied across tumor types, with an overall prevalence of 9.4%. Patients with endometrial tumors had the highest proportion of patients with dMMR at 49/164 (29.9%). Patients with cervical tumors had the lowest prevalence of dMMR with 6/221 (2.7%) patients. The prevalence of dMMR was similar across most demographic characteristics. In the dMMR population, co-occurring MLH1 and PMS2 protein loss across all tumor types was observed most commonly, in 48/70 (68.6%) patients.

Conclusions: These data highlight the importance of dMMR testing in patients with advanced solid tumors in China to optimize biomarker testing and treatment decisions.

Keywords

China / DNA mismatch repair deficiency / epidemiology / immune checkpoint inhibitor / microsatellite instability / prevalence

References

[1] G. M. Li, “Mechanisms and Functions of DNA Mismatch Repair,” Cell Research 18, no. 1 (2008): 85–98, https://doi.org/10.1038/cr.2007.115.

[2] R. Bonneville, M. A. Krook, E. A. Kautto, et al., “Landscape of Microsatellite Instability Across 39 Cancer Types,” JCO Precis Oncol 2017 (2017), https://doi.org/10.1200/po.17.00073.

[3] M. H. M. Schmidt and C. E. Pearson, “Disease-Associated Repeat Instability and Mismatch Repair,” Dna Repair (2016): 38117–38126, https://doi.org/10.1016/j.dnarep.2015.11.008.

[4] T. O. Sillo, A. D. Beggs, D. G. Morton, and G. Middleton, “Mechanisms of Immunogenicity in Colorectal Cancer,” British Journal of Surgery 106, no. 10 (2019): 1283–1297, https://doi.org/10.1002/bjs.11204.

[5] M. Baretti and D. T. Le, “DNA Mismatch Repair in Cancer,” Pharmacology & Therapeutics (2018): 18945–18962, https://doi.org/10.1016/j.pharmthera.2018.04.004.

[6] T. André, K. K. Shiu, T. W. Kim, et al., “Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer,” New England Journal of Medicine 383, no. 23 (2020): 2207–2218, https://doi.org/10.1056/NEJMoa2017699.

[7] A. Marabelle, D. T. Le, P. A. Ascierto, et al., “Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study,” Journal of Clinical Oncology 38, no. 1 (2020): 1–10, https://doi.org/10.1200/jco.19.02105.

[8] FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication. 2017. Accessed September 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.

[9] KEYTRUDA® (Pembrolizumab) Injection, for Intravenous Use: U.S. Prescribing Information. 2022. Accessed: September 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf.

[10] S. Kang, Y. Na, S. Y. Joung, et al., “The Significance of Microsatellite Instability in Colorectal Cancer After Controlling for Clinicopathological Factors,” Medicine 97, no. 9 (2018): e0019, https://doi.org/10.1097/md.0000000000010019.

[11] M. Lorenzi, M. Amonkar, J. Zhang, S. Mehta, and K.-L. Liaw, “Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review,” Journal of Oncology 2020 (2020), https://doi.org/10.1155/2020/1807929.

[12] D. M. O'Malley, G. M. Bariani, P. A. Cassier, et al., “Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study,” Journal of Clinical Oncology 40, no. 7 (2022): 752–761, https://doi.org/10.1200/jco.21.01874.

[13] L. A. Diaz, K. K. Shiu, T. W. Kim, et al., “Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study,” The Lancet Oncology 23, no. 5 (2022): 659–670, https://doi.org/10.1016/s1470-2045(22)00197-8.

[14] Y. J. Kang, S. O'Haire, F. Franchini, et al., “A Scoping Review and Meta-Analysis on the Prevalence of Pan-Tumour Biomarkers (dMMR, MSI, High TMB) in Different Solid Tumours,” Scientific Reports 12, no. 1 (2022): 20495, https://doi.org/10.1038/s41598-022-23319-1.

[15] D. S. P. Tan, Y. M. Kim, M.-C. Lim, et al. Real-World Data on Prevalence of MSI-H/dMMR Across 6 Solid Tumor Types in Asia. 2022; 33, https://doi.org/10.1016/j.annonc.2022.10.289.

[16] T. E. Soumerai, M. T. A. Donoghue, C. Bandlamudi, et al., “Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer,” Clinical Cancer Research 24, no. 23 (2018): 5939–5947, https://doi.org/10.1158/1078-0432.Ccr-18-0412.

[17] M. Cui, P. Li, Y. Mao, et al., “Implication of Microsatellite Instability in Chinese Cohort of Human Cancers,” Cancer Management and Research 12, (2020): 10287–10295, https://doi.org/10.2147/cmar.S274187.

[18] Y. Jin, H. Li, P. Zhang, et al., “The Regulatory Approvals of Immune Checkpoint Inhibitors in China and the United States: A Cross-National Comparison Study,” International Journal of Cancer 152, no. 11 (2023): 2351–2361, https://doi.org/10.1002/ijc.34427.

[19] Y. K. Kang, N. Boku, T. Satoh, et al., “Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet 390, no. 10111 (2017): 2461–2471, https://doi.org/10.1016/s0140-6736(17)31827-5.

[20] D. Zamarin, R. A. Burger, M. W. Sill, et al., “Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study,” Journal of Clinical Oncology 38, no. 16 (2020): 1814–1823, https://doi.org/10.1200/JCO.19.02059.

[21] M. L. Chen, J. Y. Chen, J. Hu, et al., “Comparison of Microsatellite Status Detection Methods in Colorectal Carcinoma,” International Journal of Clinical and Experimental Pathology 11, no. 3 (2018): 1431–1438.

[22] F. Dedeurwaerdere, K. B. Claes, J. Van Dorpe, et al., “Comparison of Microsatellite Instability Detection by Immunohistochemistry and Molecular Techniques in Colorectal and Endometrial Cancer,” Scientific Reports 11, no. 1 (2021): 12880, https://doi.org/10.1038/s41598-021-91974-x.

[23] A. N. Bartley, A. M. Mills, E. Konnick, et al., “Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer,” Archives of Pathology & Laboratory Medicine 146, no. 10 (2022): 1194–1210, https://doi.org/10.5858/arpa.2021-0632-CP.

[24] P. Vikas, H. Messersmith, C. Compton, et al., “Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline,” Journal of Clinical Oncology 41, no. 10 (2023): 1943–1948, https://doi.org/10.1200/jco.22.02462.

[25] F. H. Wang, X. T. Zhang, Y. F. Li, et al., “The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2021,” Cancer Communications (London) 41, no. 8 (2021): 747–795, https://doi.org/10.1002/cac2.12193.

[26] FDA. VENTANA MMR RxDx Panel – P200019. 2021. Accessed: September 2025, https://www.fda.gov/medical-devices/recently-approved-devices/ventana-mmr-rxdx-panel-p200019.

[27] S. Adachi, J. I. Kimata, K. Hanami, et al., “Applicability of the FDA-Approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma,” Applied Immunohistochemistry & Molecular Morphology 32, no. 1 (2024): 24–31, https://doi.org/10.1097/pai.0000000000001170.

[28] S. Koppikar, A. Oaknin, K. G. Babu, et al., “Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis, Treatment and Follow-Up of Patients With Endometrial Cancer,” ESMO Open 8, no. 1 (2023): 100774, https://doi.org/10.1016/j.esmoop.2022.100774.

[29] E. Puliga, S. Corso, F. Pietrantonio, and S. Giordano, “Microsatellite Instability in Gastric Cancer: Between Lights and Shadows,” Cancer Treatment Reviews (2021): 95102175, https://doi.org/10.1016/j.ctrv.2021.102175.

[30] B. A. Weinberg, J. Xiu, M. R. Lindberg, et al., “Molecular Profiling of Biliary Cancers Reveals Distinct Molecular Alterations and Potential Therapeutic Targets,” Journal of Gastrointestinal Oncology 10, no. 4 (2019): 652–662,

[31] V. W. Silva, G. Askan, T. D. Daniel, et al., “Biliary Carcinomas: Pathology and the Role of DNA Mismatch Repair Deficiency,” Chinese Clinical Oncology 5, no. 5 (2016): 62,

[32] Q. Xi, H. Kage, M. Ogawa, et al., “Genomic Landscape of Endometrial, Ovarian, and Cervical Cancers in Japan From the Database in the Center for Cancer Genomics and Advanced Therapeutics,” Cancers (Basel) 16, no. 1 (2023), https://doi.org/10.3390/cancers16010136.

RIGHTS & PERMISSIONS

2025 Merck & Co., Inc and The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.